Bioxyne LimitedASX: BXN

Appendix 4C Revised

· Issued by Bioxyne Limited

Filed with ASX · · 12 pages · English

• Record $18.4 million quarterly Cash Receipts, representing a 149% increase on Q2 FY25 and a 43% increase on Q1 FY26. • $2.5 million positive Q2 cash flow from operating activities • Completed dual listing on the Frankfurt Stock Exchange (ticker: PR8.F) on 13 October 2025, enhancing liquidity and access for European investors • Executed exclusive import, manufacture, and supply agreement with Cur

Bioxyne Limited on 6ix

In the deck

Story so far

Earlier from Bioxyne

Later from Bioxyne

All Bioxyne news releases